Maternal characteristics associated with pregnancy exposure to FDA category C, D, and X drugs in a Canadian population

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 3, 2008, Pages 270-277

  Yang, Tubao ^a,b,c   Walker, Mark C ^b,c   Krewski, Daniel ^b,d   Yang, Qiuying ^b,c   Nimrod, Carl ^g   Garner, Peter ^g   Fraser, William ^e   Olatunbosun, Olufemi ^f   Wen, Shi Wu ^a,b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d RISK SCIENCES INTERNATIONAL   (Canada)

^e UNIVERSITY OF MONTREAL   (Canada)

^f UNIVERSITY OF SASKATCHEWAN   (Canada)

^g NONE

Author keywords

Chronic diseases; FDA pregnancy risk classification; Parity; Pregnancy; Prescriptions; Saskatchewan; Social assistance; Teenage pregnancy

Indexed keywords

DRUG;

ADULT; ARTICLE; CANADA; CHRONIC DISEASE; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG SAFETY; FEMALE; FETUS RISK; FOOD AND DRUG ADMINISTRATION; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; RANDOM SAMPLE; RISK FACTOR; SOCIAL CARE;

ADULT; AGE FACTORS; CHRONIC DISEASE; CONFIDENCE INTERVALS; DATABASES, FACTUAL; DRUG TOXICITY; DRUG UTILIZATION; FEMALE; HUMANS; LOGISTIC MODELS; ODDS RATIO; PARITY; PHARMACEUTICAL PREPARATIONS; PREGNANCY; PREGNANCY COMPLICATIONS; PRESCRIPTIONS, DRUG; RISK FACTORS; SASKATCHEWAN; SOCIOECONOMIC FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 40949123220     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1538     Document Type: Article

References (21)

1. Rajkumar SV. Thalidomide: tragic past and promising future. Mayo Clin Proc 2004; 79: 899-903.
2. Lagoy CT, Joshi N, Cragan JD, Rasmussen SA. Medication use during pregnancy and lactation: an urgent call for public health action. J Women's Health 2005; 14: 104-109.
3. Food Drug Administration. Requirements on content and format of labeling for human prescription drug and biological products. Fed Regist 2006; 71: 3921-3997.
4. Barron WM, Lindheimer MD. Preface and guidelines for prescribing drugs to pregnant women. In Medical Disorders During Pregnancy, Barron WM, Lindheimer MD (eds). MO: Mosby-Year Book, Inc.: St. Louis, 1991; IX-XII.
5. Masters PA, O'Bryan TA, Zurlo J, Miller D, Joshi N. Trimethoprim-Sulfamethoxazole revisited. Arch Intern Med 2003; 163: 402-410.
6. Riley EH, Fuentes-Afflick E, Jackson RA, et al. Correlates of prescription drug use during pregnancy. J Women's Health 2005; 14: 401-409.
7. Buitendijk S, Bracken MB. Medication in early pregnancy: prevalence of use and relationship to maternal characteristics. Am J Obstet Gynecol 1991; 165: 33-40.
8. Rubin JD, Ferencz C, Loffredo C. Use of prescription and non-prescription drugs in pregnancy. The Baltimore-Washington Infant Study Group. J Clin Epidemiol 1993; 46: 581-589
9. Garriguet D. Medication use among pregnant women. Health Rep 2006; 17: 9-18.
10. Lee E, Maneno MK, Smith L, et al. National patterns of medication use during pregnancy. Pharmcoepidemiol Drug Saf 2006; 15: 537-545.
11. Amann U, Egen-Lappe V, Strunz-Lehner C, Hasford J. Antibiotics in pregnancy: analysis of potential risks and determinants in a large German statutory sickness fund population. Pharmacoepidemiol Drug Saf 2006; 15: 327-337.
12. Shi WuWen, Qiuying Yang, Peter Garner, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006; 194: 961-966.
13. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45: 197-203.
14. Bakker MK, Jentink J, Vroom F, et al. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 2006; 113: 559-568.
15. Williams JI, Young W. A summary on the quality of health care administrative databases in Canada. In Patterns of Health Care in Ontario. The ICES Practice Atlas, Goel V, Williams JI, Anderson GM, Blackstien-Hirsch P, Fooks C, Naylor CD (eds), 2nd edn. Canadian Medical Association: Ottawa, 1996.
16. Rothman KJ. Modern Epidemiology (2nd edn). Little, Brown and Company: Boston, 1998.
17. Schieve LA, Handler A, Hershow R, Persky V, Davis F. Urinary tract infection during pregnancy: its association with maternal morbidity and perinatal outcome. Am J Public Health 1994; 84: 405-410.
18. Naber KG. Survey on antibiotic usage in the treatment of urinary tract infections. J Antimicrob Chemother 2000; 46: 49-52.
19. Huang E, Stafford RS. National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. Arch intern Med 2002; 162: 41-47.
20. Wen SW, Walker M. Risk of fetal exposure to folic acid antagonists. J Obstet Gynaecol Can 2004; 26: 475-480.
21. Hernandez-diaz S. Prescription of medications during pregnancy: accidents, compromises,and uncertainties. Pharmacoepidemiol Drug Saf 2006; 15: 613-617.